Barclays’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Barclays’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1	Closed	-$116	–	5395
2024 Q1	$116	Hold	1	–	–	﹤0.01%	4997
2023 Q4	$27	Sell	1 -127	-99%	-$2.13K	﹤0.01%	5191
2023 Q3	$2.58K	Hold	128	–	–	﹤0.01%	4441
2023 Q2	$3.32K	Hold	128	–	–	﹤0.01%	4300
2023 Q1	$2.66K	Hold	128	–	–	﹤0.01%	4875
2022 Q4	$2.61K	Sell	128 -241	-65%	-$4.54K	﹤0.01%	5066
2022 Q3	$10K	Hold	369	–	–	﹤0.01%	4321
2022 Q2	$10K	Sell	369 -173	-32%	-$7.69K	﹤0.01%	4643
2022 Q1	$43K	Buy	+542	New	+$66.9K	﹤0.01%	4176

Other funds holding VINC

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's VINC Position: Q2 2024 in Review

Barclays sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 1 share — an estimated $116 sold.

Barclays first reported a position in VINC in Q1 2022 and held it in 9 quarters. The position peaked at $43K in Q1 2022. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

Barclays reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Barclays sold 1 Vincerx Pharma, Inc. Common Stock share in Q2 2024, an estimated $116.
Barclays first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
Barclays's Vincerx Pharma, Inc. Common Stock position peaked at $43K in Q1 2022.
27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.